Lenz Therapeutics Inc (LENZ) Stock Price, Quote & News

Company Profile

LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, Cal...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7000

Website: www.lenz-tx.com

Address:

201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States

NYTWben Jan. 17 at 4:03 PM

$LENZ I finally got my VIZZ samples. I'll start in a week and report back my experience.

0 · Reply

dbears729 Jan. 16 at 6:46 PM

$LENZ major SJP marketing taking off, sales team deployed, rev generating ramping up, huge TAM, better long lasting results than competitors, FDA approval on horizon, high float low volume. 🤤🤤🤤🤤🧨🚀🌝

1 · Reply

Paddy444 Jan. 16 at 5:57 PM

$LENZ I Better saddle up here before I give to many tricks away. I think someone spiked my cocktail today.. when people get here I will ask. Approved need here- significant- gun show starting Q2- I forgot the rest but I always put 2 socks on Value hunter here.. value to come here That damn lady with saying betting daily is the same.. maybe she doesn't understand bush maintenance on the way up, early value, left over popcorn for the cheerleaders.. longevity, later and stay cool

0 · Reply

done897 Jan. 16 at 5:00 PM

$LENZ One bonfire there was a lady.. guest- she had told me earlier in my friends kitchen while I was dancing.. "is it really the time for that"? perhaps she will be seen by others at another bonfire She did say one other goofy thing at the fire but it stuck- "bla bla Paddy.. you bet like all the others but you bet long and they bet everyday" you are no better she said What a crock of shit.. time matters.. diligence matters.. the daily on mild diligence under no stress and emotions matters.. diversification into different sectors matters.. bush maintence inj the way up matters.. 444 Numbers here.. soon stay cool taddered boy here hehee light the fire wouylkd ya

0 · Reply

Max_Regards Jan. 16 at 4:19 PM

$LENZ viewer count consistently rising we were at 1,150 viewers a few months ago. At 1,255 currently, a slow growth but showing that more retail investors are becoming aware. A lot of that growth was just from December its self. Direct consumer campaign should provide further viewer count too if its message is reaching the masses. Have a nice weekend everyone.

0 · Reply

BeefStewart Jan. 14 at 7:55 PM

$LENZ crazy to start a position at these levels?

2 · Reply

Max_Regards Jan. 14 at 7:51 PM

$LENZ seeing how much this moves on just a “tiny” bit of buyers momentum is amazing. I know for a fact this is a winner. We just need the cards to hit right. SJP direct consumer campaign success plus word of mouth will be crucial. Results and side effects are still 10x better than Vuity. If the retail public were to get wind of this and buy in then I easily see us reaching $50-$100 a share by end of year. Here’s to hope 🤞🏼

1 · Reply

SirRahal Jan. 14 at 4:34 PM

$LENZ Short Squeeze? How high do we think this could run before getting a pullback?

3 · Reply

Max_Regards Jan. 14 at 3:46 PM

$LENZ yeah $LENZ Has a Negative Beta for sure. It always pumps when market wide dumps happen. Mostly due to shorts initiating early covers to offset market loss on other positions or margins.

0 · Reply

Max_Regards Jan. 13 at 12:49 PM

$LENZ high risk, high reward Short interest is declining. Shorts are becoming satisfied and will wait to see the direct consumer campaign goes before increaseing or decreasing further.

1 · Reply

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Jan 7, 2026, 5:08 PM EST - 9 days ago

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Jan 5, 2026, 8:00 AM EST - 12 days ago

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

Dec 17, 2025, 9:02 AM EST - 4 weeks ago

LENZ Therapeutics: Was That A Market Overreaction?

Dec 4, 2025, 1:58 PM EST - 6 weeks ago

LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 1, 2025, 8:30 AM EST - 6 weeks ago

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

Nov 25, 2025, 4:05 PM EST - 7 weeks ago

LENZ Therapeutics to Present at Upcoming Investor Conferences

Nov 5, 2025, 1:21 PM EST - 2 months ago

LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 8:00 AM EST - 2 months ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Oct 29, 2025, 8:00 AM EDT - 2 months ago

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

Sep 30, 2025, 8:05 AM EDT - 3 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 30, 2025, 8:00 AM EDT - 3 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 10, 2025, 3:05 PM EDT - 4 months ago

LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 2:49 PM EDT - 4 months ago

LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 5 months ago

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

Jul 31, 2025, 4:05 PM EDT - 6 months ago

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

Jul 30, 2025, 8:00 AM EDT - 6 months ago

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 29, 2025, 1:32 PM EDT - 6 months ago

LENZ Therapeutics: Undervalued Ahead Of PDUFA

Jul 28, 2025, 8:00 AM EDT - 6 months ago

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

Jul 7, 2025, 8:00 AM EDT - 6 months ago

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Jul 1, 2025, 4:23 PM EDT - 7 months ago

LENZ Therapeutics: Presbyopia Eyedrops Look Promising

May 9, 2025, 10:33 AM EDT - 9 months ago

LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript

May 9, 2025, 9:03 AM EDT - 9 months ago

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 7, 2025, 4:05 PM EDT - 9 months ago

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 4:30 PM EDT - 9 months ago

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

Apr 30, 2025, 4:30 PM EDT - 9 months ago

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Apr 7, 2025, 8:00 AM EDT - 10 months ago

LENZ Therapeutics: Freedom From Reading Glasses

Mar 27, 2025, 5:33 PM EDT - 10 months ago

LENZ Therapeutics Stock Is Attractive Before PDUFA

Mar 19, 2025, 8:09 PM EDT - 10 months ago

LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 4:05 PM EDT - 10 months ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 11, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

Mar 3, 2025, 8:00 AM EST - 11 months ago

LENZ Therapeutics to Host Commercial Day on April 15, 2025

Feb 24, 2025, 8:00 AM EST - 11 months ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2024, 11:43 AM EST - 1 year ago

LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 1:51 PM EDT - 1 year ago

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

Oct 27, 2024, 9:00 PM EDT - 1 year ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Oct 21, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

ABOS

Aug 30, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics: Upcoming PDUFA, Strong Data, Some Risks

Aug 16, 2024, 7:43 PM EDT - 1 year ago

LENZ Therapeutics, Inc. (LENZ) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

Aug 7, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 10, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

May 30, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

May 11, 2024, 7:26 AM EDT - 1 year ago

LENZ Therapeutics, Inc. (LENZ) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 1, 2024, 4:01 PM EDT - 1 year ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Apr 3, 2024, 7:49 AM EDT - 1 year ago

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

NYTWben Jan. 17 at 4:03 PM

$LENZ I finally got my VIZZ samples. I'll start in a week and report back my experience.

0 · Reply

dbears729 Jan. 16 at 6:46 PM

1 · Reply

Paddy444 Jan. 16 at 5:57 PM

0 · Reply

done897 Jan. 16 at 5:00 PM

0 · Reply

Max_Regards Jan. 16 at 4:19 PM

0 · Reply

BeefStewart Jan. 14 at 7:55 PM

$LENZ crazy to start a position at these levels?

2 · Reply

Max_Regards Jan. 14 at 7:51 PM

1 · Reply

SirRahal Jan. 14 at 4:34 PM

$LENZ Short Squeeze? How high do we think this could run before getting a pullback?

3 · Reply

Max_Regards Jan. 14 at 3:46 PM

$LENZ yeah $LENZ Has a Negative Beta for sure. It always pumps when market wide dumps happen. Mostly due to shorts initiating early covers to offset market loss on other positions or margins.

0 · Reply

Max_Regards Jan. 13 at 12:49 PM

$LENZ high risk, high reward Short interest is declining. Shorts are becoming satisfied and will wait to see the direct consumer campaign goes before increaseing or decreasing further.

1 · Reply

Max_Regards Jan. 12 at 1:23 PM

$LENZ another week of pain? Bring it on 😎

3 · Reply

Dreamit2 Jan. 10 at 2:21 AM

$LENZ Any drug on the market will have adverse side effects with some people. Vizz is no different, aceclidine is safer than Vuity's pilocarpine with less side affects. The FDA knows this, and still pilocarpine is still used today. Don't get scared out of a good investment that just got launched less than three months ago.

0 · Reply

Lunr2024 Jan. 9 at 11:57 PM

$LENZ Thanks to the short sellers, I finally got the opportunity to buy at $15. For every dollar it drops, I'll add 10% to my position. My next buy order is set at $14; hopefully, the short sellers won't let me down.

0 · Reply

NYTWben Jan. 9 at 4:20 PM

$LENZ I have been long round trip from from 14 to 50 and back again. The short interest is strangely high in the face of several big coming catalyst : South Korea Approval, China Approval, UAE Approval, Dubai Approval, and the Sarah Jessica Parker campaign. This price action just presents a buying opportunity. At this point the low float plus the heavy shorts there is a good opportunity for a short squeeze.

1 · Reply

Max_Regards Jan. 9 at 4:05 PM

$LENZ just here vibing. The public has spoken and its likes VIZZ Now it’s a matter of if management rises to the challenge of establishing a start up into a titan Or A big fish comes in and buys the company and based on the 5-10 year future cash projections it would leave us all with many dollars.

3 · Reply

BeefStewart Jan. 8 at 8:11 PM

$LENZ Hi, I have no position here but I watch the stock somewhat. Can you kindly explain what you meant when you said Shawn Olsson signaled intent to sell 40k shares but you then state that he holds only over 4k shares? Any clarification would be greatly appreciated. Thank you and good luck!

3 · Reply

Max_Regards Jan. 8 at 7:14 PM

$LENZ update on insider buy confusion. The files on http://SEC.GOV for Jan 6th are clearly a bonus based incentive program for executive leadership. The vesting schedules are essentially a 5 year vesting plan. Exercise price on the options is $16 dollars. Meaning in the next 5 years it is within their best interest to have the stock appreciate in value and hold value for the next 5 years because that is when they can exercise them. This was given to CCO, CFO and CMO Total options/shares = 294,600 Value at issue $16/share = $4,713,600 Value in 5 years at $100/share = 29,460,000 Yeah, if I were them, I’d be working my ass off to make VIZZ the biggest underdog success in history.

7 · Reply

Max_Regards Jan. 8 at 7:00 PM

$LENZ hey yall, just here to get again show you that our local short seller @Nicothebest has zero support to their claims. He claimed CCO Shawn Olsson has sold shares by claiming the form 144 on http://SEC.GOV Form 144 is not a confirmation of a sale, form 4 is a confirmation of a completed sale. Form 144 is just the “intent” to sell. Not only that but the sale is also based on a 10b5-1 trading plan which he had to enter into 90 days prior to any sale. This is to discourage insider trading activity. CCO’s form 144 filing shows intent to sell 40,000 shares. That total sale has not happened, Gemini did find that he filed a form 4 and completed sale of 10,000 shares. They continue to hold 4,733 shares He then immediate turned around and bought 10,000 shares worth of options contracts for a total of 53,000 options My professional opinion, COO is diversifying portions of their holding at $LENZ as they have a significant concentration risk.

6 · Reply

SirRahal Jan. 8 at 6:30 PM

$LENZ Is now a good time to buy in?

2 · Reply

longshot45 Jan. 8 at 5:47 PM

$LENZ hmm literally no support. Preliminary earnings didnt look that bad to me.

1 · Reply

Max_Regards Jan. 8 at 4:28 PM

$LENZ @Nicothebest this man claims two things that I cannot find proof of. 1) Adverse reactions in 61 year old woman on Dec 23rd 2025 - not a single search I dig in finds any information. 2) COO sold stock - again no source to back this up and $LENZ doesn’t even list a COO on their executive team webpage. Remember - short sellers love fear and uncertainty and the ability to make up BS info on the spot is 10x easier than being in the position to prove it false. So @Nicothebest is either an omniscient short seller or actually has inside information. An act that is highly illegal.

11 · Reply

Max_Regards Jan. 8 at 3:46 PM

$LENZ don’t forget this stock will now be a source of tax loss harvesting for the 2025 tax year. Q1 is the gold standard here. If adoption in Q1 does not meet expectations then we have a true issue. Because it could mean the ghost of Vuity still haunts the consumers wallet.

2 · Reply

Market Cap	567.60M
Revenue (ttm)	0.00
Net Income (ttm)	-49.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,254,800
Avg Vol	1,204,942
Day's Range	N/A - N/A
Shares Out	31.29M
Stochastic %K	80%
Beta	0.50
Analysts	Strong Sell
Price Target	$53.00